drugset / Trial / NCT00232687

A Switch Study of BMS-337039 in Schizophrenic Out-patients

NCT00232687

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this clinical research study is to evaluate the safety and tolerability of two switching strategies from risperidone to aripiprazole over a period of 12 weeks in out-patients who are treated in a general psychiatric practice setting and who are currently experiencing efficacy and/or safety/tolerability issues while on risperidone.

Timeline

Start
2005-06-01
Primary completion
2007-04-01
Completion
2007-04-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 10 mg Oral
Comparator Aripiprazole Other / unclassified 30 mg Oral

Indications